Array
(
[id] => 1133
[catid] => 203
[title] => ESAIC focused guideline for the use of cardiac biomarkers in perioperative risk evaluation
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1133.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:23:33
[updatetime] => 2024-01-11 15:23:33
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://guide.medlive.cn/guideline/28939
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => ESAIC
[pdf] =>
[tjyjyw] =>
[lyyw] => We suggest that routine measurement of postoperative cardiac troponins may be used for the prediction of some postoperative outcomes, in particular 30-day all-cause mortality. Level of evidence: Low；Recommendation grade:Weak.
[laiyuan] => 我们建议常规测量术后心肌肌钙蛋白可用于预测一些术后结果，特别是30天的全因死亡率。（证据等级：低；推荐强度：弱推荐）
[znzldj] => A
[_inputtime] => 1704957813
[_updatetime] => 1704957813
[_nrjc] =>
[_nrsh] =>
)
推荐意见
我们建议常规测量术后心肌肌钙蛋白可用于预测一些术后结果，特别是30天的全因死亡率。（证据等级：低；推荐强度：弱推荐）
We suggest that routine measurement of postoperative cardiac troponins may be used for the prediction of some postoperative outcomes, in particular 30-day all-cause mortality. Level of evidence: Low；Recommendation grade:Weak.
证据评价方法：GRADE
指南质量等级：A
年份：2023
国家：ESAIC
Array
(
[id] => 1134
[catid] => 203
[title] => ESAIC focused guideline for the use of cardiac biomarkers in perioperative risk evaluation
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1134.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:23:33
[updatetime] => 2024-01-11 15:23:33
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://guide.medlive.cn/guideline/28939
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => ESAIC
[pdf] =>
[tjyjyw] =>
[lyyw] => The routine measurement of postoperative cardiac troponins within a biomarker-enhanced management program to improve outcome should only be used in the context of clinical research.Level of evidence: Very low；Recommendation grade:No recommendation.
[laiyuan] => 常规的术后心肌肌钙蛋白测量在生物标记物增强管理计划中，以改善结果应仅用于临床研究。（证据等级：很低；推荐强度：不推荐）
[znzldj] => A
[_inputtime] => 1704957813
[_updatetime] => 1704957813
[_nrjc] =>
[_nrsh] =>
)
推荐意见
常规的术后心肌肌钙蛋白测量在生物标记物增强管理计划中，以改善结果应仅用于临床研究。（证据等级：很低；推荐强度：不推荐）
The routine measurement of postoperative cardiac troponins within a biomarker-enhanced management program to improve outcome should only be used in the context of clinical research.Level of evidence: Very low；Recommendation grade:No recommendation.
证据评价方法：GRADE
指南质量等级：A
年份：2023
国家：ESAIC
Array
(
[id] => 1135
[catid] => 192
[title] => ESAIC focused guideline for the use of cardiac biomarkers in perioperative risk evaluation
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1135.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:23:33
[updatetime] => 2024-01-11 15:23:33
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://guide.medlive.cn/guideline/28939
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => ESAIC
[pdf] =>
[tjyjyw] =>
[lyyw] => We suggest that routine measurement of preoperative B-type natriuretic peptides may be used to help evaluate the risk of some adverse outcomes in non-cardiac surgery. Level of evidence: Moderate；Recommendation grade:Weak.
[laiyuan] => 我们建议术前常规测定B型钠尿肽可能有助于评估非心脏手术中某些不良结局的风险。（证据等级：中等；推荐强度：弱推荐）
[znzldj] => A
[_inputtime] => 1704957813
[_updatetime] => 1704957813
[_nrjc] =>
[_nrsh] =>
)
推荐意见
我们建议术前常规测定B型钠尿肽可能有助于评估非心脏手术中某些不良结局的风险。（证据等级：中等；推荐强度：弱推荐）
We suggest that routine measurement of preoperative B-type natriuretic peptides may be used to help evaluate the risk of some adverse outcomes in non-cardiac surgery. Level of evidence: Moderate；Recommendation grade:Weak.
证据评价方法：GRADE
指南质量等级：A
年份：2023
国家：ESAIC
Array
(
[id] => 1136
[catid] => 192
[title] => ESAIC focused guideline for the use of cardiac biomarkers in perioperative risk evaluation
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1136.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:23:33
[updatetime] => 2024-01-11 15:23:33
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://guide.medlive.cn/guideline/28939
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => ESAIC
[pdf] =>
[tjyjyw] =>
[lyyw] => We suggest that the addition of preoperative B-type natriuretic peptides to clinical risk scores might be used to improve the prediction of some postoperative events, in particular 30-day major adverse cardiac events. Level of evidence: Very low；Recommendation grade:Weak.
[laiyuan] => 我们建议将术前b型利钠肽添加到临床风险评分中，可以用于改善一些术后事件的预测，特别是30天的主要不良心脏事件。（证据等级：很低；推荐强度：弱推荐）
[znzldj] => A
[_inputtime] => 1704957813
[_updatetime] => 1704957813
[_nrjc] =>
[_nrsh] =>
)
推荐意见
我们建议将术前b型利钠肽添加到临床风险评分中，可以用于改善一些术后事件的预测，特别是30天的主要不良心脏事件。（证据等级：很低；推荐强度：弱推荐）
We suggest that the addition of preoperative B-type natriuretic peptides to clinical risk scores might be used to improve the prediction of some postoperative events, in particular 30-day major adverse cardiac events. Level of evidence: Very low；Recommendation grade:Weak.
证据评价方法：GRADE
指南质量等级：A
年份：2023
国家：ESAIC
Array
(
[id] => 1137
[catid] => 191
[title] => ESAIC focused guideline for the use of cardiac biomarkers in perioperative risk evaluation
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1137.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:23:33
[updatetime] => 2024-01-11 15:23:33
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://guide.medlive.cn/guideline/28939
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => ESAIC
[pdf] =>
[tjyjyw] =>
[lyyw] => The use of preoperative BNP/NT-proBNP-enhanced management to improve outcomes should be limited to the context of clinical research. Level of evidence: No data；Recommendation grade:No recommendation.
[laiyuan] => 术前BNP/NT-proBNP强化管理的使用应限于临床研究的背景下。（证据等级：无数据；推荐强度：不推荐）
[znzldj] => A
[_inputtime] => 1704957813
[_updatetime] => 1704957813
[_nrjc] =>
[_nrsh] =>
)
推荐意见
术前BNP/NT-proBNP强化管理的使用应限于临床研究的背景下。（证据等级：无数据；推荐强度：不推荐）
The use of preoperative BNP/NT-proBNP-enhanced management to improve outcomes should be limited to the context of clinical research. Level of evidence: No data；Recommendation grade:No recommendation.
证据评价方法：GRADE
指南质量等级：A
年份：2023
国家：ESAIC
Array
(
[id] => 1138
[catid] => 203
[title] => ESAIC focused guideline for the use of cardiac biomarkers in perioperative risk evaluation
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1138.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:23:33
[updatetime] => 2024-01-11 15:23:33
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://guide.medlive.cn/guideline/28939
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => ESAIC
[pdf] =>
[tjyjyw] =>
[lyyw] => Routine measurement of postoperative BNP/NT-proBNP to help evaluate the risk of adverse outcomes should only be used in the context of clinical research. Level of evidence:Very low；Recommendation grade:No recommendation.
[laiyuan] => 常规测量术后BNP/NT-proBNP以帮助评估不良后果的风险，只能在临床研究中使用。（证据等级：很低；推荐强度：不推荐）
[znzldj] => A
[_inputtime] => 1704957813
[_updatetime] => 1704957813
[_nrjc] =>
[_nrsh] =>
)
推荐意见
常规测量术后BNP/NT-proBNP以帮助评估不良后果的风险，只能在临床研究中使用。（证据等级：很低；推荐强度：不推荐）
Routine measurement of postoperative BNP/NT-proBNP to help evaluate the risk of adverse outcomes should only be used in the context of clinical research. Level of evidence:Very low；Recommendation grade:No recommendation.
证据评价方法：GRADE
指南质量等级：A
年份：2023
国家：ESAIC
Array
(
[id] => 1139
[catid] => 191
[title] => ESAIC focused guideline for the use of cardiac biomarkers in perioperative risk evaluation
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1139.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:23:33
[updatetime] => 2024-01-11 15:23:33
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://guide.medlive.cn/guideline/28939
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => ESAIC
[pdf] =>
[tjyjyw] =>
[lyyw] => The routine addition of BNP/NT-proBNP to clinical risk scores to improve the prediction of postoperative events should only be used in the context of clinical research. Level of evidence:Very low；Recommendation grade:No recommendation.
[laiyuan] => 常规在临床风险评分中加入BNP/NT-proBNP以提高对术后事件的预测，这种方法只能在临床研究的背景下使用。（证据等级：很低；推荐强度：不推荐）
[znzldj] => A
[_inputtime] => 1704957813
[_updatetime] => 1704957813
[_nrjc] =>
[_nrsh] =>
)
推荐意见
常规在临床风险评分中加入BNP/NT-proBNP以提高对术后事件的预测，这种方法只能在临床研究的背景下使用。（证据等级：很低；推荐强度：不推荐）
The routine addition of BNP/NT-proBNP to clinical risk scores to improve the prediction of postoperative events should only be used in the context of clinical research. Level of evidence:Very low；Recommendation grade:No recommendation.
证据评价方法：GRADE
指南质量等级：A
年份：2023
国家：ESAIC
Array
(
[id] => 1140
[catid] => 203
[title] => ESAIC focused guideline for the use of cardiac biomarkers in perioperative risk evaluation
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1140.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:23:33
[updatetime] => 2024-01-11 15:23:33
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://guide.medlive.cn/guideline/28939
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => ESAIC
[pdf] =>
[tjyjyw] =>
[lyyw] => The use of postoperative BNP/NT-proBNP-enhanced management to improve outcomes should only be used in the context of clinical research. Level of evidence:No data；Recommendation grade:No recommendation.
[laiyuan] => 术后BNP/NT-proBNP强化管理改善预后应仅在临床研究的背景下使用。（证据等级：无数据；推荐强度：不推荐）
[znzldj] => A
[_inputtime] => 1704957813
[_updatetime] => 1704957813
[_nrjc] =>
[_nrsh] =>
)
推荐意见
术后BNP/NT-proBNP强化管理改善预后应仅在临床研究的背景下使用。（证据等级：无数据；推荐强度：不推荐）
The use of postoperative BNP/NT-proBNP-enhanced management to improve outcomes should only be used in the context of clinical research. Level of evidence:No data；Recommendation grade:No recommendation.
证据评价方法：GRADE
指南质量等级：A
年份：2023
国家：ESAIC
Array
(
[id] => 1101
[catid] => 30
[title] => Consensus Guidelines for Perioperative Care for Emergency Laparotomy Enhanced Recovery After Surgery (ERAS) Society Recommendations Part 2—Emergency Laparotomy: Intra-and Postoperative Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1101.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:23:32
[updatetime] => 2024-01-11 15:23:32
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241558/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the International ERAS Society
[pdf] =>
[tjyjyw] =>
[lyyw] => To minimize the risk of aspiration after induction of anesthesia rapid control of the airway with intubation using a fast-acting muscle relaxant such as
succinylcholine 1–2 mg kg -1 or rocuronium 0.9 to 1.2 mg kg -1 for placement of an endotracheal tube should be used. We recommend the use of cricoid pressure according to the practitioner’s respective national guidelines. Drugs for induction of anesthesia should be selected and dosed appropriately to maintain hemodynamic stability.Evidence level: Moderate；Recommendation grade: Strong
[laiyuan] => 为了减少麻醉诱导后的误吸风险，使用速效肌松剂，如置入气管导管时应使用琥珀胆碱1-2mg/kg或罗库溴铵0.9-1.2mg/kg。我们建议根据执业医师各自的国家指南使用环状软骨压力。麻醉诱导时应选择合适的药物和剂量，以维持血流动力学稳定（证据级别：中；推荐强度：强推荐）
[znzldj] => B
[_inputtime] => 1704957812
[_updatetime] => 1704957812
[_nrjc] =>
[_nrsh] =>
)
推荐意见
为了减少麻醉诱导后的误吸风险，使用速效肌松剂，如置入气管导管时应使用琥珀胆碱1-2mg/kg或罗库溴铵0.9-1.2mg/kg。我们建议根据执业医师各自的国家指南使用环状软骨压力。麻醉诱导时应选择合适的药物和剂量，以维持血流动力学稳定（证据级别：中；推荐强度：强推荐）
To minimize the risk of aspiration after induction of anesthesia rapid control of the airway with intubation using a fast-acting muscle relaxant such as
succinylcholine 1–2 mg kg -1 or rocuronium 0.9 to 1.2 mg kg -1 for placement of an endotracheal tube should be used. We recommend the use of cricoid pressure according to the practitioner’s respective national guidelines. Drugs for induction of anesthesia should be selected and dosed appropriately to maintain hemodynamic stability.Evidence level: Moderate；Recommendation grade: Strong
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the International ERAS Society
Array
(
[id] => 1102
[catid] => 30
[title] => Consensus Guidelines for Perioperative Care for Emergency Laparotomy Enhanced Recovery After Surgery (ERAS) Society Recommendations Part 2—Emergency Laparotomy: Intra-and Postoperative Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1102.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:23:32
[updatetime] => 2024-01-11 15:23:32
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241558/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the International ERAS Society
[pdf] =>
[tjyjyw] =>
[lyyw] => There is no evidence to recommend one anesthetic agent over another for maintenance of anesthesia.Level of evidence: Low；Recommendation grade: Weak
[laiyuan] => 没有证据去推荐一种麻醉药物优于另一种麻醉药维持麻醉。（证据级别：低；推荐强度：弱推荐）
[znzldj] => B
[_inputtime] => 1704957812
[_updatetime] => 1704957812
[_nrjc] =>
[_nrsh] =>
)
推荐意见
没有证据去推荐一种麻醉药物优于另一种麻醉药维持麻醉。（证据级别：低；推荐强度：弱推荐）
There is no evidence to recommend one anesthetic agent over another for maintenance of anesthesia.Level of evidence: Low；Recommendation grade: Weak
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the International ERAS Society
